摘要
目的 分析肾病综合征患者采用低分子肝素辅助治疗的临床效果及价值。方法 选择2015年1月—2017年12月该院收诊治疗的肾病综合征患者74例为研究对象,根据随机单双号抽签方式分为观察组(单号,37例)与对照组(双号,37例),对照组单纯采用泼尼松治疗,观察组在其基础上使用低分子肝素辅助治疗,对比两组临床治疗效果,检测各组患者治疗前后凝血指标(激活凝血酶Ⅲ、D-二聚体、纤维蛋白原、凝血酶原时间、部分凝血活酶时间)及生化指标(血肌酐、尿素氮、24 h尿蛋白定量)变化,统计比较两组患者治疗后并发症总发生率。结果 观察组患者通过辅助低分子肝素治疗后,总有效率(97.30%)高于对照组,差异有统计学意义(χ^(2)=7.400,P<0.05);观察组患者治疗后激活凝血酶Ⅲ指标、凝血酶原时间、部分凝血活酶时间均高于对照组,其他凝血指标低于对照组,差异有统计学意义(P<0.05);观察组患者治疗后生化指标相应检测结果均低于对照组,差异有统计学意义(P<0.05);两组患者并发症总发生率比较差异无统计学意义(P>0.05)。结论 肾病综合征患者采用低分子肝素辅助治疗能够具有确切疗效,能够有效调节患者凝血功能及生化指标,提倡运用推广。
Objective To analyze the clinical effect and value of low molecular weight heparin adjuvant therapy in patients with nephrotic syndrome. Methods The research subjects selected 74 patients with nephrotic syndrome admitted to the hospital from January 2015 to December 2017 for treatment and were divided into observation group(odd number, 37 cases) and the control group(double number, 37 cases), the control group was treated with prednisone alone, and the observation group was treated with low molecular weight heparin on the basis of it. The clinical treatment effects of the two groups were compared, and the blood coagulation indexes(activated thrombin Ⅲ, D-dimer, fibrinogen, prothrombin time, partial thromboplastin time) and bio-chemical indexes(serum creatinine, blood urea nitrogen, 24 h urine protein quantification) were detected before and after treat-ment in each group. The total incidence of complications after treatment in the two groups was statistically compared. Results After adjuvant low molecular weight heparin treatment, the total effective rate of the observation group was 97.30% higher than that of the control group,the difference was statistically significant (χ2=7.400,P<0.05). The activated thrombin Ⅲ indexes, prothrombin time and partial thromboplastin time in the observation group were higher than those in the control group, and other coagulation indexes were lower than those in the control group, the difference was statistically significant(P<0.05). The corresponding detection results of biochemical indicators in the observation group after treatment were lower than those in the control group, the difference was statistically significant(P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups(P>0.05). Conclusion Adjuvant treatment of patients with nephrotic syndrome with low-molecular-weight heparin can have definite curative effects, and can effectively regulate the blood coagulation function and biochemical indicators of pat
作者
陈莹
CHEN Ying(Department of Nephrology,Lianyungang Sheng'an Hospital,Lianyungang,Jiangsu Province,222199 China)
出处
《世界复合医学》
2022年第3期183-186,共4页
World Journal of Complex Medicine
关键词
低分子肝素
肾病综合征
疗效
凝血指标
生化指标
Low molecular weight heparin
Nephrotic syndrome
Efficacy
Coagulation index
Biochemical index
